Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18009
Title: Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
Austin Authors: Lim, Lucy ;Thompson, Alexander;Patterson, Scott J ;George, Jacob;Strasser, Simone;Lee, Alice;Sievert, William;Nicoll, Amanda;Desmond, Paul;Roberts, Stuart;Marion, Kaye;Bowden, Scott;Locarnini, Stephen;Angus, Peter
Affiliation: Victorian Liver Transplant Unit
Gastroenterology and Hepatology
Gastroenterology Department, St Vincent's Hospital, Melbourne, Victoria, Australia
Molecular Research & Development Laboratory, Victorian Infectious Diseases Reference Laboratory, Melbourne, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia
Storr Liver Centre, Westmead Millennium Institute for Medical Research, Westmead Hospital & University of Sydney, Sydney, NSW, Australia
AW Morrow Gastroenterology & Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
Gastroenterology Department, Concord Hospital, Sydney, NSW, Australia
Gastroenterology Department, Monash Medical Centre, Melbourne, Victoria, Australia
Gastroenterology & Hepatology Department, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Gastroenterology Department, Eastern Health, Melbourne, Victoria, Australia
Gastroenterology Department, Alfred Hospital, Melbourne, Victoria, Australia
Mathematical & Geospatial Sciences Department, RMIT University, Melbourne, Victoria, Australia
Issue Date: Jun-2017
Date: 2016-12-22
Publication information: Liver International : Official Journal of the International Association for the Study of the Liver 2017; 37(6): 827-835
Abstract: Multidrug-resistant HBV continues to be an important clinical problem. The TDF-109 study demonstrated that TDF±LAM is an effective salvage therapy through 96 weeks for LAM-resistant patients who previously failed ADV add-on or switch therapy. We evaluated the 5-year efficacy and safety outcomes in patients receiving long-term TDF±LAM in the TDF-109 study. A total of 59 patients completed the first phase of the TDF-109 study and 54/59 were rolled over into a long-term prospective open-label study of TDF±LAM 300 mg daily. Results are reported at the end of year 5 of treatment. At year 5, 75% (45/59) had achieved viral suppression by intent-to-treat analysis. Per-protocol assessment revealed 83% (45/54) were HBV DNA undetectable. Nine patients remained HBV DNA detectable, however 8/9 had very low HBV DNA levels (<264IU/mL) and did not meet virological criteria for virological breakthrough (VBT). One patient experienced VBT, but this was in the setting of documented non-compliance. The response was independent of baseline LAM therapy or mutations conferring ADV resistance. Four patients discontinued TDF, one patient was lost to follow-up and one died from hepatocellular carcinoma. Long-term TDF treatment appears to be safe and effective in patients with prior failure of LAM and a suboptimal response to ADV therapy. These findings confirm that TDF has a high genetic barrier to resistance is active against multidrug-resistant HBV, and should be the preferred oral anti-HBV agent in CHB patients who fail treatment with LAM and ADV.
URI: https://ahro.austin.org.au/austinjspui/handle/1/18009
DOI: 10.1111/liv.13331
ORCID: 
Journal: Liver International : Official Journal of the International Association for the Study of the Liver
PubMed URL: 27896895
Type: Journal Article
Subjects: antiviral therapy
hepatitis B
hepatology
viral hepatitis
Appears in Collections:Journal articles

Show full item record

Page view(s)

24
checked on Oct 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.